HC Wainwright Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 128.10% from the stock’s previous close.

Several other research firms also recently issued reports on ANRO. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. BTIG Research lifted their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wedbush cut their target price on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a research report on Thursday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average target price of $35.57.

Alto Neuroscience Stock Down 6.4%

ANRO stock traded down $1.49 during mid-day trading on Thursday, hitting $21.92. 395,172 shares of the company were exchanged, compared to its average volume of 251,039. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $25.17. The firm’s 50 day simple moving average is $19.09 and its 200 day simple moving average is $14.63. The firm has a market cap of $700.26 million, a P/E ratio of -10.06 and a beta of 2.52.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. On average, sell-side analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. Commodore Capital LP bought a new position in Alto Neuroscience during the fourth quarter worth $32,453,000. Artia Global Partners LP bought a new position in shares of Alto Neuroscience in the fourth quarter valued at about $520,000. 683 Capital Management LLC bought a new position in shares of Alto Neuroscience in the fourth quarter valued at about $1,153,000. Spruce Street Capital LP acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth about $3,967,000. Finally, AdvisorShares Investments LLC acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth about $785,000.

Alto Neuroscience News Summary

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating and set a $30.00 price target (about 40% upside from current levels), providing some buy-side support amid the trial news. Chardan reaffirmed buy
• Positive Sentiment: JonesTrading cut its price target from $49 to $44 but kept a “buy” rating, leaving a large implied upside that may attract value-seeking investors if confidence in the broader pipeline holds. JonesTrading lowers PT but stays buy
• Neutral Sentiment: Company announces a strategic pivot: Alto is shifting focus to ALTO-207 after the ALTO-101 topline readout — this indicates pipeline prioritization but brings execution and timeline uncertainty. Alto shifts focus to ALTO-207
• Negative Sentiment: Alto reported that ALTO-101 did not reach statistical significance on the trial’s primary endpoint — the core reason for the stock sell-off and heightened short-term risk to valuation. Topline data announcement
• Negative Sentiment: Market coverage highlights the trial miss and accompanying stock decline, reinforcing negative sentiment among investors and media. Investing.com coverage
• Negative Sentiment: Additional reporting on the failed schizophrenia study amplifies investor concern about ALTO-101 and near-term commercial prospects. MSN article
• Negative Sentiment: Wedbush trimmed its price target to $21.00 and moved to “neutral,” signaling diminished near-term upside and adding downward pressure from the sell-side. Wedbush lowers PT to neutral

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.